ChiCTR-IPC-15006618
结束
/
/
/
2015-06-17
/
/
knee osteoarthritis
膝關節手法治療對退化性膝關節炎的效用
膝關節手法治療對退化性膝關節炎的效用
膝關節手法治療對退化性膝關節炎的效用
随机平行对照
其它
1:1 Randomization
/
Hong Kong College of Family Physicians
/
104
/
2015-06-30
1990-01-01
/
1) Aged ≥ 45 to ≤ 75 years old; 2) Diagnosis of knee OA based on clinical criteria as defined by the American Rheumatology Association; 3) Have experienced moderate to severe knee pain for at least 3 months, defined as a score of 3 or more (0-6 ordinal response scale) on the question “What is the average level of your left/right knee pain?” 4) Involvement of anterior knee compartment and exhibit 2 of the following criteria on initial assessment: pain on direct compression of the patella against the femoral condyles with the knee in full extension, tenderness on palpation of the posterior surface of the patella, pain on resisted knee extension, and pain with isometric quadriceps contraction against suprapatellar resistance with the knee in slight flexion.；
请登录查看1) Previous operation either open or arthroscopic, on the referring knee 2) Body mass index ≥ 35 kg/m2 3) Any knee injections within 1 month 4) Inflammatory or post-infectious knee arthritis 5) Daily use of opioid medication 6) Co-morbidity severe enough to prevent participation in the study protocol like attendance at scheduled appointments 7) Fixed flexion deformity >5 degree and varus and valgus deformity > 15 degree made manual mobilization of the patella impossible.；
请登录查看Professor Regina Wing Shan SIT
/
Professor Regina Wing Shan SIT的其他临床试验
Division of Family Medicine and Primary Health Care, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04